Tanaka Kazuki, Tanigawa Naoki, Song Isaiah, Komatsu Toru, Kuriki Yugo, Tanaka Yukari, Fukudo Shin, Urano Yasuteru, Fukuda Shinji
Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
Systems Biology Program, Graduate School of Media and Governance, Keio University, Fujisawa, Kanagawa, Japan.
Front Microbiol. 2023 Jul 7;14:1179534. doi: 10.3389/fmicb.2023.1179534. eCollection 2023.
Irritable bowel syndrome (IBS) has no clinically accepted biomarkers even though it affects a large number of individuals worldwide. To address this lack of understanding, we evaluated peptidase activity in fecal samples from 35 patients with diarrheal IBS without symptom exacerbation (IBS-n) and 35 healthy subjects using a library of 384 fluorescent enzymatic substrate probes. IBS-n patients had high trypsin-like peptidase activity for cleavage of C-terminal lysine and arginine residues and low elastase-like activity for cleavage of C-terminal serine and glycine residues. These fluorescent probe library data, together with diagnostic machine-learning techniques, were able to accurately predict IBS-n. This approach can be used to diagnose diseases where no clinically accepted biomarkers exist, in which fecal enzyme activity is altered and also suggests that the development of new therapies targeting enzyme activities is possible.
肠易激综合征(IBS)尽管在全球影响着大量人群,但目前尚无临床公认的生物标志物。为了解决这一认知不足的问题,我们使用一个包含384种荧光酶底物探针的文库,评估了35例无症状加重的腹泻型IBS患者(IBS-n)和35名健康受试者粪便样本中的肽酶活性。IBS-n患者对C末端赖氨酸和精氨酸残基的切割具有较高的胰蛋白酶样肽酶活性,而对C末端丝氨酸和甘氨酸残基的切割具有较低的弹性蛋白酶样活性。这些荧光探针文库数据,结合诊断性机器学习技术,能够准确预测IBS-n。这种方法可用于诊断不存在临床公认生物标志物、粪便酶活性发生改变的疾病,也表明开发针对酶活性的新疗法是有可能的。